Sera Prognostics (NASDAQ: SERA) has announced publication of a new subgroup analysis from the PRIME trial demonstrating that its PreTRM Test-guided care in first-time pregnancies significantly improved neonatal outcomes, including a 22% reduction in neonatal intensive care unit (NICU) admissions.
The findings were published in The Journal of Maternal-Fetal & Neonatal Medicine and highlight the clinical value of early risk stratification using the PreTRM Test combined with accessible interventions in women in their first pregnancy, a large population in which risk is otherwise difficult to predict.
In a statement, Zhenya Lindgardt, president and CEO of Sera, commented, “This study demonstrates the power of tailoring pregnancy care for first-time pregnancies. These results show that the PreTRM Test-guided care pathway can improve outcomes in this large subgroup within a pregnant population where the least information is available to evaluate risk. Delivering on the potential to improve affordability, an important result for patients, providers, and payers.”
